Quang Pham Sells Shares of Cadrenal Therapeutics

Quang Pham, the Chairman, CEO, and Interim CFO of Cadrenal Therapeutics, Inc., sold 2,127 shares of the company on June 25, 2026. The shares were sold at an average price of $3.00, amounting to a total value of $6,381. This transaction was part of a planned sale under Rule 10b5-1, which allows insiders to set up a trading plan for selling stocks.

Insider Buying and Selling at Cadrenal Therapeutics, Inc.

Quang Pham has been actively trading shares of Cadrenal Therapeutics, selling multiple blocks of shares throughout June 2026. On June 26, he sold 9,029 shares at $3.05 each, and earlier on June 23, he sold 2,277 shares at $3.20. These transactions are part of a series of sales under a pre-arranged trading plan.

Other Institutional Activity in Cadrenal Therapeutics

Vanguard Capital Management LLC opened a new position in Cadrenal Therapeutics, acquiring 45,201 shares valued at approximately $231,429. Geode Capital Management, LLC increased its holdings by 7,098 shares, bringing its total to 21,626 shares worth about $110,724, marking a 48.9% increase. BlackRock, Inc. also expanded its stake by 1,974 shares, now holding 5,496 shares valued at $28,140, reflecting a 56.0% increase. Meanwhile, JPMorgan Chase & Co maintained its position with 7,500 shares valued at $31,875.

Cadrenal Therapeutics, Inc. Stock Up 98.1%

Shares of NasdaqCM:CVKD traded near $3.05 on Saturday. Cadrenal Therapeutics has a market capitalization of approximately $8.8 million. The stock has experienced a 52-week low of $2.55 and a high of $14.64. Its 50-day moving average stands at $4.84, while the 200-day moving average is $8.25. The company exhibits a current ratio of 2.68 and a quick ratio of 2.17, indicating its ability to cover short-term obligations.

Analysts Set New Price Targets

On April 7, 2026, HC Wainwright & Co. maintained its "buy" rating for Cadrenal Therapeutics with a price target of $13. Analysts have set a mean price target of $27.67 for the stock, with a consensus rating of "strong buy" based on three analyst opinions.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc. is a biotechnology company based in Ponte Vedra, Florida. It focuses on developing innovative treatments for severe immune and thrombotic conditions. The company is advancing Tecarfarin, an oral vitamin K antagonist in Phase 3 trials, along with other candidates targeting blood clot-related disorders. Founded in 2022, Cadrenal Therapeutics operates with a small team of five employees under the leadership of CEO Quang Pham.

Bottom Line

Quang Pham's recent sale of shares in Cadrenal Therapeutics is part of a planned trading strategy, not necessarily reflecting a lack of confidence in the company. Investors often monitor insider transactions to gauge management's outlook. With a strong buy consensus from analysts and a focus on life-saving therapies, Cadrenal Therapeutics remains a company of interest. Remember, insider transactions are reported after the fact and don't always indicate future performance.